Two Blood Monocytic Biomarkers (CCL15 and p21) Combined with the Mini-Mental State Examination Discriminate Alzheimer’s Disease Patients from Healthy Subjects
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
Background: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder. In AD, monocytes migrate across the blood-brain barrier and differentiate into microglia, are linked to inflammatory responses and display age-dependent decreases in telomere lengths. Methods: Six monocyte-specific chemokines and the (telomere-associated) tumor suppressor proteins p53 and p21 were determined by multiplex immunoassay in plasma and monocyte extracts of patients with AD or mild cognitive impairment, and levels were compared between patients and controls (without cognitive impairment). Results: CCL15 (macrophage inflammatory protein-1δ), CXCL9 (monokine-induced by interferon-γ) and p21 levels were decreased in monocytes of AD patients compared with controls. Conclusion: The combination of monocytic CCL15 and p21 together with the Mini-Mental State Examination enables to differentiate AD patients from controls with high specificity and sensitivity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The levels of p16INK4a have been reported to be elevated in neurons from AD patients [194,198,199,200], as well as in neurons from AD mouse models [195].”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [200]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
Telomeres shorten during ageing of human fibroblasts
Harley, C. B., Futcher, A. B., & Greider, C. W. (1990) · Nature · doi:10.1038/345458a0 · Cited by 5,750
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
Current concepts in mild cognitive impairment
Petersen, R. C., Doody, R., Kurz, A., Mohs, R. C., Morris, J. C., Rabins, P. V., Ritchie, K., Rossor, M., Thal, L., & Winblad, B. (2001) · Archives of Neurology · doi:10.1001/archneur.58.12.1985 · Cited by 4,781
p21 is a universal inhibitor of cyclin kinases
Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., & Beach, D. (1993) · Nature · doi:10.1038/366701a0 · Cited by 3,368
Wyss-Coray (2006) · doi:10.1038/nm1484 · Cited by 1,284
Tsou, C.-L., Peters, W., Si, Y., Slaymaker, S., Aslanian, A. M., Weisberg, S. P., Mack, M., & Charo, I. F. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29919 · Cited by 1,152
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins
Ray, S., Britschgi, M., Herbert, C., Takeda-Uchimura, Y., Boxer, A., Blennow, K., Friedman, L. F., Galasko, D. R., Jutel, M., Karydas, A., et al. (2007) · Nature Medicine · doi:10.1038/nm1653 · Cited by 1,048
Macrophage inflammatory protein-1
Maurer, M., & von Stebut, E. (2004) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2003.10.019 · Cited by 767
Secretion of Neurotoxins by Mononuclear Phagocytes Infected with HIV-1
Giulian, D., Vaca, K., & Noonan, C. A. (1990) · Science · doi:10.1126/science.2148832 · Cited by 620
Elaborate interactions between the immune and nervous systems
Steinman, L. (2004) · Nature Immunology · doi:10.1038/ni1078 · Cited by 556
Identifying and validating biomarkers for Alzheimer's disease
Humpel, C. (2011) · Trends in Biotechnology · doi:10.1016/j.tibtech.2010.09.007 · Cited by 484
Self-citationRole of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease
Zhao, L., Ma, Q.-L., Calon, F., Harris-White, M. E., Yang, F., Lim, G. P., Morihara, T., Ubeda, O. J., Ambegaokar, S., Hansen, J. E., et al. (2006) · Nature Neuroscience · doi:10.1038/nn1630 · Cited by 317
Fiala, M., Liu, Q. N., Sayre, J., Pop, V., Brahmandam, V., Graves, M. C., & Vinters, H. V. (2002) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2002.00994.x · Cited by 307
Malm, T. M., Koistinaho, M., Pärepalo, M., Vatanen, T., Ooka, A., Karlsson, S., & Koistinaho, J. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.09.009 · Cited by 301
Intrathecal Chemokine Synthesis in Mild Cognitive Impairment and Alzheimer Disease
Galimberti, D., Schoonenboom, N., Scheltens, P., Fenoglio, C., Bouwman, F., Venturelli, E., Guidi, I., Blankenstein, M. A., Bresolin, N., & Scarpini, E. (2006) · Archives of Neurology · doi:10.1001/archneur.63.4.538 · Cited by 289
Evidence That Aging And Amyloid Promote Microglial Cell Senescence
Flanary, B. E., Sammons, N. W., Nguyen, C., Walker, D., & Streit, W. J. (2007) · Rejuvenation Research · doi:10.1089/rej.2006.9096 · Cited by 272
Cellular senescence in vivo: Its relevance in ageing and cardiovascular disease
Erusalimsky, J. D., & Kurz, D. J. (2005) · Experimental Gerontology · doi:10.1016/j.exger.2005.04.010 · Cited by 252
Sokolova, A., Hill, M. D., Rahimi, F., Warden, L. A., Halliday, G. M., & Shepherd, C. E. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00188.x · Cited by 249
ISHIZUKA, K., KIMURA, T., IGATA‐YI, R., KATSURAGI, S., TAKAMATSU, J., & MIYAKAWA, T. (1997) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.1997.tb02375.x · Cited by 245
Fiala, M., Zhang, L., Gan, X.-H., Sherry, B. A., Taub, D. D., Graves, M. C., Hama, S., Way, D., Weinand, M. E., Witte, M. H., et al. (1998) · PubMed Central · Cited by 229
Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer’s disease
Galimberti, D., Fenoglio, C., Lovati, C., Venturelli, E., Guidi, I., Corrà, B., Scalabrini, D., Clerici, F., Mariani, C., Bresolin, N., et al. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.10.007 · Cited by 209
Vaziri, H., & Benchimol, S. (1996) · Experimental Gerontology · doi:10.1016/0531-5565(95)02025-x · Cited by 206
Sun, Y.-X., Minthon, L., Wallmark, A., Warkentin, S., Blennow, K., & Janciauskiene, S. (2003) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000071001 · Cited by 180
Interferon-β directly influences monocyte infiltration into the central nervous system
Floris, S., Ruuls, S. R., Wierinckx, A., van der Pol, S. M. A., Döpp, E., van der Meide, P. H., Dijkstra, C. D., & De Vries, H. E. (2002) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(02)00098-x · Cited by 179
Bermejo, P., Martín-Aragón, S., Benedí, J., Susín, C., Felici, E., Gil, P., Ribera, J. M., & Villar, Á. M. (2008) · Immunology Letters · doi:10.1016/j.imlet.2008.02.002 · Cited by 178
Blasko, I., Lederer, W., Oberbauer, H., Walch, T., Kemmler, G., Hinterhuber, H., Marksteiner, J., & Humpel, C. (2006) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000089137 · Cited by 170
Self-citationMicroglia, Scavenger Receptors, and the Pathogenesis of Alzheimer’s Disease
El Khoury, J., Hickman, S. E., Thomas, C. A., Loike, J. D., & Silverstein, S. C. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00036-0 · Cited by 159
CSF biomarkers for mild cognitive impairment
Blennow, K. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01368.x · Cited by 151
Marksteiner, J., Kemmler, G., Weiss, E. M., Knaus, G., Ullrich, C., Mechtcheriakov, S., Oberbauer, H., Auffinger, S., Hinterhölzl, J., Hinterhuber, H., et al. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.03.011 · Cited by 142
Self-citationCSF biomarkers for Alzheimer’s disease: use in early diagnosis and evaluation of drug treatment
Blennow, K. (2005) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.5.5.661 · Cited by 140
Youn, B., Zhang, S., Lee, E. K., Park, D. H., Broxmeyer, H. E., Murphy, P. M., Locati, M., Pease, J. E., Kim, K. K., Antol, K., et al. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.11.5201 · Cited by 121
Mattsson, N., Tabatabaei, S., Johansson, P., Hansson, O., Andreasson, U., Månsson, J.-E., Johansson, J.-O., Olsson, B., Wallin, A., Svensson, J., et al. (2011) · NeuroMolecular Medicine · doi:10.1007/s12017-011-8147-9 · Cited by 118
Chemokines in serum and cerebrospinal fluid of Alzheimer's disease patients
Galimberti, D., Schoonenboom, N. S. M., Scarpini, E. A., & Scheltens, P. (2003) · Annals of Neurology · doi:10.1002/ana.10531 · Cited by 116
Peripheral Chemokine Receptors, Their Ligands, Cytokines and Alzheimer's Disease
Reale, M., Iarlori, C., Feliciani, C., & Gambi, D. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-14203 · Cited by 109
Grodstein, F., van Oijen, M., Irizarry, M. C., Rosas, H. D., Hyman, B. T., Growdon, J. H., & De Vivo, I. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001590 · Cited by 104
Cytokines in Alzheimer's Disease and Vascular Dementia
Angelopoulos, P., Agouridaki, H., Vaiopoulos, H., Siskou, E., Doutsou, K., Costa, V., & Baloyiannis, S. I. (2008) · International Journal of Neuroscience · doi:10.1080/00207450701392068 · Cited by 100
Xu, X., Yang, D., Wyss‐Coray, T., Yan, J. S., Gan, L., Sun, Y. N., & Mucke, L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.13.7547 · Cited by 95
MCP-1 in Alzheimer’s disease patients: A-2518G polymorphism and serum levels
Fenoglio, C., Galimberti, D., Lovati, C., Guidi, I., Gatti, A., Fogliarino, S., Tiriticco, M., Mariani, C. B., Forloni, G., Pettenati, C., et al. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.11.008 · Cited by 94
Serum levels of interleukin-6 are not elevated in patients with Alzheimer's disease
van Duijn, C. M., Albert Hofman, D., & Nagelkerken, L. M. (1990) · Neuroscience Letters · doi:10.1016/0304-3940(90)90666-w · Cited by 80
Identification of Human Macrophage Inflammatory Proteins 1α and 1β as a Native Secreted Heterodimer
Guan, E., Wang, J., & Norcross, M. A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m006327200 · Cited by 78
Burns, A. S., Byrne, E. J., & Maurer, K. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09420-5 · Cited by 77
Davenport, C. M., Sevastou, I. G., Hooper, C., & Pocock, J. M. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06485.x · Cited by 71
Increased Pro-Inflammatory Response by Dendritic Cells from Patients with Alzheimer's Disease
Ciaramella, A., Bizzoni, F., Salani, F., Vanni, D., Spalletta, G., Sanarico, N., Vendetti, S., Caltagirone, C., & Bossù, P. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1257 · Cited by 70
Malm, T., Magga, J. M., Kuh, G. F., Vatanen, T., Koistinaho, M., & Koıstınaho, J. (2008) · Glia · doi:10.1002/glia.20726 · Cited by 56
The origin and fate of the monocyte.
Volkman, A. (1970) · PubMed · Cited by 55
Bioplex analysis of plasma cytokines in Alzheimer’s disease and mild cognitive impairment
Lee, K. S., Chung, J. H., Lee, K. H., Shin, M.-J., Oh, B. H., & Hong, C. H. (2008) · Immunology Letters · doi:10.1016/j.imlet.2008.09.004 · Cited by 50
Soluble cell adhesion molecules in monocytes of Alzheimer’s disease and mild cognitive impairment
Hochstrasser, T., Weiss, E., Marksteiner, J., & Humpel, C. (2010) · Experimental Gerontology · doi:10.1016/j.exger.2009.10.005 · Cited by 49
Self-citationIarlori, C., Gambi, D., Gambi, F., Lucci, I., Feliciani, C., Salvatore, M., & Reale, M. (2005) · Experimental Gerontology · doi:10.1016/j.exger.2005.04.007 · Cited by 48
P53-mediated G1/S checkpoint dysfunction in lymphocytes from Alzheimer's disease patients
Zhou, X., & Jia, J. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.11.024 · Cited by 44
The tumour suppressor p53 regulates the expression of amyloid precursor protein (APP)
Cuesta, A., Zambrano, A., Royo, M., & Pascual, A. (2009) · Biochemical Journal · doi:10.1042/bj20081793 · Cited by 35
En route to early diagnosis of Alzheimer's disease – are we there yet?
Fradinger, E. A., & Bitan, G. (2005) · Trends in biotechnology · doi:10.1016/j.tibtech.2005.09.002 · Cited by 23
[Alzheimer's disease lesions: from morphology to cell biology].
Hauw, J., Seilhean, D., Piette, F., Uchihara, T., & Duyckaerts, C. J. (1996) · PubMed · Cited by 8
Cited by
Ageing, Cellular Senescence and Neurodegenerative Disease
Kritsilis, M., V. Rizou, S., Koutsoudaki, P. N., Evangelou, K., Gorgoulis, V. G., & Papadopoulos, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102937 · Cited by 448
CXCR3 ligands in disease and therapy
Van Raemdonck, K., Van den Steen, P. E., Liekens, S., Van Damme, J., & Struyf, S. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.11.009 · Cited by 310
Stuart, M. J., & Baune, B. T. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.02.001 · Cited by 259
Marksteiner, J., Blasko, I., Kemmler, G., Koal, T., & Humpel, C. (2018) · Metabolomics · doi:10.1007/s11306-017-1297-5 · Cited by 159
Self-citationSystemic immune system alterations in early stages of Alzheimer's disease
Zhang, R., Miller, R. G., Madison, C. A., Jin, X., Honrada, R., Harris, W., Katz, J., Forshew, D. A., & McGrath, M. S. (2013) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2013.01.002 · Cited by 141
Metadata
- Authors
- Hochstrasser, T., Marksteiner, J., Defrancesco, M., Deisenhammer, E. A., Kemmler, G., & Humpel, C.
- Affiliations
- Innsbruck Medical University (AT)
- Corresponding author
- Humpel, Christian
- Venue
- Dementia and Geriatric Cognitive Disorders Extra
- Publisher
- S. Karger AG
- Published
- 2011-10-06
- Volume
- 1
- Issue
- 1
- Pages
- 297-309
- ISSN
- 1664-5464 (ISSN-L)
- PMC
- PMC3235941
- OpenAlex
- W2087886914
- Cited by
- 31
- References
- 55
- Citations by year
- 2025: 1 · 2023: 3 · 2022: 4 · 2021: 3 · 2020: 1 · 2019: 5 · 2018: 1 · 2017: 3 · 2015: 3 · 2014: 2 · 2013: 4
- FWCI
- 1.54
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/3.0/ (vor)
- creativecommons.org/licenses/by-nc/3.0/ (tdm)
- Locations
- Dementia and Geriatric Cognitive Disorders Extra (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Austrian Science Fund
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, blood biomarkers, monocytes, CCL15, p21, CXCL9, chemokines, telomere length, p53, Mini-Mental State Examination, mild cognitive impairment, plasma biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.